# A Study to Assess NEU-723 in Healthy Participants

> **NCT05633745** · PHASE1 · TERMINATED · sponsor: **Neuron23 Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** NEU-723
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05633745
- **Lead sponsor:** Neuron23 Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633745, "A Study to Assess NEU-723 in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05633745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*